Johnson and Johnson drug ‘could end premature ejaculation’

A new drug from Johnson & Johnson, developed by its subsidiary Alza, could help to combat premature ejaculation – one of the commonest male sexual dysfunctions that can lead to relationship break-ups and the erosion of self-confidence.

A recent survey from specialists writing for NetDoctor.co.uk revealed that one in ten British males admit to suffering from premature ejaculation “sometimes” or “often”, but there is currently no approved treatment for the disorder.

However, a new phase III study published in the Lancet involving 2,600 men revealed that dapoxetine, the Johnson & Johnson drug, can extend ejaculation times by 2.78 minutes in patients using the 30mg dosage and 3.32 minutes for patients receiving the 60mg dose.

Dr Jon Pryor, who led the investigations, stated: “Dapoxetine … improved patients’ perceptions of control over ejaculation, satisfaction with sexual intercourse, and overall impression of change in condition.”

“Partners benefited through improved satisfaction with sexual intercourse,” he added.

Peter Baker of the Men’s Health Forum, said the findings could be significant. He told BBC News: “There is really very little treatment for premature ejaculation so any drug which may help would be welcome.

“However, one of the major obstacles to treatment is convincing men to seek help. It is a very common problem, but many feel to embarrassed to talk to doctors and other health professionals,” he concluded.

© Adfero Ltd